Edwards Lifesciences Corp (EW) Stock Price & Analysis
Edwards Lifesciences Corp (EW) rose 1.97% to USD 87.54 as of June 9, 2026 at 22:34 UTC, according to Nexqual real-time market data.
EW last closed at USD 85.85; the session ranged USD 85.99–87.93 on volume of 2,727,870 shares. Market capitalization is $50.41B, with a 52-week range of USD 72.3–89.48 (NYQ). Source: Nexqual, June 9, 2026 at 22:34 UTC.
Key Statistics (as of June 9, 2026 at 22:34 UTC)
| Price | USD 87.54 |
|---|---|
| Change | ▲ 1.97% (up) |
| Previous Close | USD 85.85 |
| Open | USD 86.27 |
| Day Range | USD 85.99 – 87.93 |
| 52-Week Range | USD 72.3 – 89.48 |
| Volume | 2,727,870 shares |
| Market Cap | $50.41B |
| Exchange | NYQ |
Technical Analysis (EW)
Nexqual's technical model rates EW "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 9, 2026 at 22:34 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.22 (neutral) |
| vs SMA50 | Above (USD 82.46) |
| MACD | 1.37 (positive) |
Analyst Ratings (EW)
Wall Street analysts rate EW "Buy" based on 26 analysts, with a mean price target of USD 96.92 (range USD 84–110), per Nexqual as of June 9, 2026 at 22:34 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 96.92 |
| High Target | USD 110 |
| Low Target | USD 84 |
| Buy / Hold / Sell | 21 / 8 / 0 |
Earnings (EW)
| Next Earnings Date | 2026-07-23 |
|---|---|
| EPS Estimate | USD 0.74 |
| Revenue Estimate | $1.70B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.78 vs est 0.73 ▲ beat |
| 2025-12-31 | USD 0.58 vs est 0.62 ▼ miss |
| 2025-09-30 | USD 0.67 vs est 0.59 ▲ beat |
| 2025-06-30 | USD 0.67 vs est 0.62 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financials & Fundamentals (EW)
| Total Revenue | $6.30B |
|---|---|
| Revenue Growth (YoY) | +16.70% |
| Gross Margin | +77.87% |
| Operating Margin | +31.22% |
| Profit Margin | +17.39% |
| ROE | +10.46% |
| Debt / Equity | 6.81 |
| Current Ratio | 4.42 |
| Total Cash | $3.67B |
| Total Debt | $702.90M |
| Free Cash Flow | $902.14M |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Financial Health Score (EW)
Nexqual rates Edwards Lifesciences Corp's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:34 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 78%, operating 31% |
| Balance Sheet | Strong — $3.67B cash vs $703M debt, net cash position |
| Cash Flow | Solid — FCF $902M, 15% margin |
| Efficiency | Mixed — ROE 10%, ROA 8.3% |
Ownership (EW)
| Insider Ownership | +0.18% |
|---|---|
| Institutional Ownership | +94.08% |
| Shares Outstanding | 575.80M |
| Float | 573.99M |
| Short % of Float | +2.25% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
Leadership (EW)
Edwards Lifesciences Corp is led by Bernard J. Zovighian (age 57), CEO & Director, per Nexqual as of June 9, 2026 at 22:34 UTC.
| CEO & Director | Bernard J. Zovighian (age 57) |
|---|---|
| Corporate Vice President of Strategy & Corporate Development | Donald E. Bobo (age 63) |
| Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies | Daveen Chopra (age 46) |
| Corporate Vice President of EMEA, Canada, & Latin America | Annette Maria Bruls (age 54) |
| Corporate VP & CFO | Theodora Mistras (age 43) |
Major Backers & Investors (EW)
Notable institutional backers of Edwards Lifesciences Corp include Wellington Management, JPMorgan, FMR, LLC, according to Nexqual as of June 9, 2026 at 22:34 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Wellington Management | 3.82% |
| JPMorgan | 3.78% |
| FMR, LLC | 2.52% |
| Jennison Associates LLC | 2.27% |
| Fidelity | 1.29% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 23.38% |
| BlackRock | 10.43% |
| State Street | 5.78% |
| BNY Mellon | 2.91% |
| Geode Capital | 2.28% |
Source: Nexqual, June 9, 2026 at 22:34 UTC.
From Edwards Lifesciences Corp's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
- It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
- The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
- It distributes its products through a direct sales force and independent distributors.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BAX | Baxter International Inc. | USD 20.03 | ▲ 3.35% |
| BSX | Boston Scientific Corporation | USD 48.96 | ▲ 0.84% |
| RMD | ResMed Inc. | USD 196.94 | ▲ 0.46% |
| SYK | Stryker Corporation | USD 314.01 | ▲ 2.73% |
| BDX | Becton, Dickinson and Company | USD 152.04 | ▲ 0.58% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:34 UTC. This page is informational and not investment advice.